Sarepta Therapeutics Inc (SRPT) concluded trading on Thursday at a closing price of $37.31, with 3.19 million shares of worth about $119.07 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -71.08% during that period and on June 12, 2025 the price saw a loss of about -1.32%. Currently the company’s common shares owned by public are about 98.25M shares, out of which, 93.37M shares are available for trading.
Stock saw a price change of -4.85% in past 5 days and over the past one month there was a price change of 3.07%. Year-to-date (YTD), SRPT shares are showing a performance of -69.31% which decreased to -69.57% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $34.10 but also hit the highest price of $173.25 during that period. The average intraday trading volume for Sarepta Therapeutics Inc shares is 3.78 million. The stock is currently trading -3.14% below its 20-day simple moving average (SMA20), while that difference is down -20.85% for SMA50 and it goes to -62.34% lower than SMA200.
Sarepta Therapeutics Inc (NASDAQ: SRPT) currently have 98.25M outstanding shares and institutions hold larger chunk of about 90.14% of that.
The stock has a current market capitalization of $3.67B and its 3Y-monthly beta is at 0.60. It has posted earnings per share of -$2.58 in the same period. It has Quick Ratio of 2.46 while making debt-to-equity ratio of 1.18. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SRPT, volatility over the week remained 3.07% while standing at 3.83% over the month.
Stock’s fiscal year EPS is expected to drop by -178.94% while it is estimated to increase by 499.69% in next year.
Coverage by Evercore ISI stated Sarepta Therapeutics Inc (SRPT) stock as an In-line in their note to investors on May 08, 2025, suggesting a price target of $50 for the stock. On April 11, 2025, Wells Fargo Initiated their recommendations, while on April 02, 2025, H.C. Wainwright Upgrade their ratings for the stock with a price target of $75. Stock get a Sector perform rating from RBC Capital Mkts on March 31, 2025.
